About VALTHERA, LLC
ValThera is developing a novel transcatheter treatment for patients with tricuspid valve diseases, focusing on simplicity, safety, and efficiency. The solution is designed for minimally invasive implantation to address the significant unmet need in treating tricuspid regurgitation.
Development of a novel transcatheter treatment for tricuspid valve regurgitationProprietary anchoring system for precise positioning of prosthetic valvesNovel prosthetic design to prevent residual regurgitation and thrombus formationMultidisciplinary collaboration integrating clinical and cardiac imaging expertise with advanced cardiac device engineering
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to VALTHERA, LLC right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.